about
The molecular basis for the mode of action of bicyclomycinPandemic of atopic diseases--a lack of microbial exposure in early infancy?CD8+ T-cells: are they sufficient to prevent, contain or eradicate HIV-1 infection?The HIV pandemic: a forgotten crisis?New aminoacyl-tRNA synthetase inhibitors as antibacterial agents.Candida and candidiasis: the cell wall as a potential molecular target for antifungal therapy.The discovery of linezolid, the first oxazolidinone antibacterial agent.Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance.Non-human primate models for AIDS vaccine research.4'-C-substituted-2'-deoxynucleosides: a family of antiretroviral agents which are potent against drug-resistant HIV variants.The strategy of immunologic control of HIV-1 with structured treatment interruptions (STIs).Bacterial ribosomal subunit synthesis: a novel antibiotic target.West Nile virus vaccine.Bisphosphonates as chemotherapeutic agents against trypanosomatid and apicomplexan parasites.Molecular mechanisms of antibiotic resistance in gram-positive pathogens.New approaches for antigen discovery, production and delivery: vaccines for veterinary and human use.Novel adjuvant systems.Recent developments in vaccine delivery systems.Bacterial carriers and virus-like-particles as antigen delivery devices: role of dendritic cells in antigen presentation.Use of T cell epitopes for vaccine development.Vaccines for parasitic diseases.Vaccines against polysaccharide antigens.Rational drug design of DNA oligonucleotides as HIV inhibitors.Lipopolysaccharide as a target for the development of novel therapeutics in gram-negative bacteria.Unexploited viral and host targets for the treatment of human immunodeficiency virus type 1 infection.The emerging new generation of antibiotic: ketolides.HIV-1 integration as a target for antiretroviral therapy: a review.The HCMV chemokine receptor US28 is a potential target in vascular disease.1,3-beta-Glucan synthase: a useful target for antifungal drugs.Adhesion mechanisms of the Lyme disease spirochete, Borrelia burgdorferi.E. Coli MurG: a paradigm for a superfamily of glycosyltransferases.Overcoming bacterial resistance by dual target inhibition: the case of streptogramins.Antifibrogenic therapies in chronic HCV infection.Antiretroviral therapy regimens for neuro-AIDS.Strategic targeting of essential host-pathogen interactions in chlamydial disease.Structure-based inhibitor design targeting HIV-1 integrase.Histidine kinase-mediated signal transduction systems of pathogenic microorganisms as targets for therapeutic intervention.CCR5 chemokine receptors: gatekeepers of HIV-1 infection.Antibacterial drug discovery in the post-genomics era.The TB structural genomics consortium: providing a structural foundation for drug discovery.
P1433
Q28273712-930335A6-6FF8-4E57-BD49-B2B712C56BDAQ30332273-310CBF17-3675-473E-B112-854589DE6C62Q30350931-8F52EA7D-7BBE-4D04-A4BB-2B0303C3F41EQ30351044-C9CDF2EC-D617-4E9E-B405-C3C53F5DF316Q31134004-73CCF161-9041-40A6-92ED-9271E4F257E8Q33203473-60D3B1BD-E374-485B-A4D7-694D8A35CC36Q34161240-28011B6B-E847-4AAB-8248-83B8DC3ED59DQ34293880-7F04B0FB-F33D-4CAC-963A-6E2A54EE4E89Q34715769-7388F8CF-7F4F-47FA-9B4F-D420C2DDF8C5Q35010552-395ECE19-F3A2-4A27-A643-26F665DC255EQ35010557-B9A51022-DAE8-46A5-9D75-6680F38A760DQ35010561-57247347-9F99-47D4-BE81-6ED74677302EQ35010565-1E441B7C-5324-4289-A938-697AD56CCF81Q35010570-07CB8FCB-7863-47CA-B9EF-40F328D6B500Q35010574-A8AFDA3E-05EF-4FF3-AC0B-02C7C99CC464Q35010638-0D36AB85-F618-437E-924F-9864A76F9B7FQ35010641-627BA541-28EC-440E-BF23-B3DE55FC60FBQ35010646-C90C07F8-9769-4E41-918C-06294F76282CQ35010651-3344A36B-B3EF-4602-8686-A511171A6A74Q35010656-14E60BC0-88F6-4159-80CB-304D223FF807Q35010661-D83194ED-BA6B-4316-A8C5-383B8239D6BCQ35010665-C8D8C1A7-C1F1-46A8-8897-1027E58D37A5Q35010669-ED8B12FD-C49B-48B2-810A-05BC3772BE15Q35010674-9722D651-D19F-4C91-9823-FB2E8523DEF7Q35010677-FCD91884-F7BD-44A6-8020-26A94620C7D6Q35010682-4D10E079-A1AC-4A38-82DC-3B495131FD6EQ35010685-71B02F2B-2FFF-45AC-96C5-835936A89B25Q35010690-45B59853-3361-4413-8E4F-E34812812540Q35010694-77F2AB3E-D779-40D9-BD6A-AD35D68B5881Q35010698-4A0AC09B-55AA-4BDE-B7FC-AB7334BA5D84Q35010706-170DEE3F-E9AD-4A39-92C8-69B0DE1F2AC6Q35010711-2057A18F-ECB9-4AA5-9505-120AAF4A38CDQ35010717-6CDF6A56-307C-4235-9E92-DF685407470EQ35014426-DE5895B4-60FF-4197-85AF-8548D2F6CF98Q35014432-6A73B5E2-1BCE-4C5B-B0F7-1FDB4DF456E0Q35014435-374C798D-3FC9-4DC7-B556-7DC397F9201EQ35014439-5EEDFBDA-536F-4A72-ADD2-2C1E904E5415Q35014444-822E37A2-A50C-4E9E-8C55-3FD03E5990FBQ35014459-B2B1B99D-FF60-4C5B-A0EA-21E8794CF5F0Q35014466-588C76B9-CDE9-47AD-8B20-C040CD792ADC
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift van Bentham Science Publishers
@nl
wissenschaftliche Fachzeitschrift
@de
name
Current drug targets. Infectious disorders
@ast
Current drug targets. Infectious disorders
@en
Current drug targets. Infectious disorders
@es
Current drug targets. Infectious disorders
@nl
type
label
Current drug targets. Infectious disorders
@ast
Current drug targets. Infectious disorders
@en
Current drug targets. Infectious disorders
@es
Current drug targets. Infectious disorders
@nl
altLabel
Curr Drug Targets Infect Disord
@en
prefLabel
Current drug targets. Infectious disorders
@ast
Current drug targets. Infectious disorders
@en
Current drug targets. Infectious disorders
@es
Current drug targets. Infectious disorders
@nl
P3181
P1055
P1156
P1476
Current drug targets. Infectious disorders
@en